Archiv | Archiv 2018 | ASCO 2018

Welcome to Chicago 2018

ASCO 2018

Aktuelles in 100 Sekunden - Fazit

Dr. med. Friedrich Overkamp

ASCO 2018

Aktuelles in 100 Sekunden - Die Idee

Dr. med. Friedrich Overkamp

Biosimilars

ASCO 2018

Biosimilar ABP 980

PD Dr. med. Hans-Christian Kolberg

ASCO 2018

Biosimilars ASCO 2018

Dr. med. Friedrich Overkamp

Ovarialkarzinom - 100 Sekunden

ROSELLA

ASCO 2025

Zuverlässige Option für Patientinnen mit…

Prof. Dr. med. Diana Lüftner

CheckMate 77T

ASCO 2025

Guter Langzeitbenefit für perioperative…

PD Dr. med. Wilfried Eberhardt

OUTBACK

ASCO 2025

Bedeutung von PROs

Prof. Dr. med. Beyhan Ataseven

Mammakarzinom

ASCO 2018

EBC HR+/HER2-: TAILORx: Chemoendocrine therapy vs.…

Prof. Dr. med. Peter A. Fasching

ASCO 2018

PI3K & AKT Pathway: SANDPIPER - Taselisib, PAKT -…

Prof. Dr. med. Andreas Schneeweiss

ASCO 2018

ASCO 2018 - Mammakarzinom

PD Dr. med. Hans-Christian Kolberg

ASCO 2018

Alpelisib (ALP) + fulvestrant (FUL) for advanced breast…

Prof. Dr. med. Peter A. Fasching

ASCO 2018

MBC HR+/HER2-: Sacituzumab govitecan (anti-Trop-2-SN-38…

Prof. Dr. med. Andreas Schneeweiss

ASCO 2018

Persistence of circulating tumor cells in high risk EBC…

Prof. Dr. med. Peter A. Fasching

ASCO 2018

EBC HER2+: PERSEPHONE (6 vs. 12 months trastuzumab) &…

PD Dr. med. Hans-Christian Kolberg

ASCO 2018

MBC HER2+: Trastuzumab deruxtecan in subjects…

Prof. Dr. med. Peter A. Fasching

ASCO 2018

ASCO 2018 - Mammakarzinom

Prof. Dr. med. Peter A. Fasching

ASCO 2018

MBC HR+/HER2-: MONALEESA-3, PALOMA-2, Monarch 3

Prof. Dr. med. Andreas Schneeweiss

ASCO 2018

TNBC: GeparNuevo - The addition of durvalumab to a…

Prof. Dr. med. Andreas Schneeweiss

ASCO 2018

Irradiation therapy: EORTC Trial 22922/10925 and…

PD Dr. med. Hans-Christian Kolberg

ASCO 2018

EBC BRCA+: Neoadjuvant talazoparib for operable breast…

PD Dr. med. Hans-Christian Kolberg

ASCO 2018

CDK 4/6 Update

Prof. Dr. med. Achim Wöckel

ASCO 2018

EBC BRCA+: Prophylactic irradiation to the…

Prof. Dr. med. Peter A. Fasching

Multiples Myelom

ASCO 2018

OPTIMISMM

Prof. Dr. med. Katja Weisel

ASCO 2018

Hematologic Malignancies - Plasma Cell Dyscrasia

Prof. Dr. med. Katja Weisel

ASCO 2018

A.R.R.O.W.

Prof. Dr. med. Katja Weisel

Melanom

ASCO 2018

Melanom Highlights

Prof. Dr. med. Axel Hauschild

Supportive Therapie

ASCO 2018

Arthralgieschmerz, Polyneuropathie, Rash

Prof. Dr. med. Karin Jordan

Urogenitale Tumoren

ASCO 2018

mRCC: CARMENA - Cytoreductive nephrectomy aus der Sicht…

PD Dr. med. Peter J. Goebell

ASCO 2018

Metastasiertes Urothelkarzinom

PD Dr. med. Peter J. Goebell

ASCO

Immunantwort

PD Dr. med. Peter J. Goebell

ASCO 2018

mRCC: CARMENA - Cytoreductive nephrectomy aus der Sicht…

Prof. Dr. med. Viktor Grünwald

ASCO 2018

Blasenkarzinom - Übersicht und PD-L1 Testung

PD Dr. med. Peter J. Goebell

ASCO 2018

Nierenzellkarzinom

PD Dr. med. Peter J. Goebell

ASCO 2018

Immunonkologie Prostatakarzinom

PD Dr. med. Peter J. Goebell

Weitere

ASCO 2018

ASCO Voices

PD Dr. med. Peter J. Goebell

ASCO 2018

CML & NSCLC

Dr. med. Friedrich Overkamp

ASCO 2018

Kopf-Hals-Tumoren

Prof. Dr. med. Viktor Grünwald

ASCO 2018

Weichgewebssarkome

Prof. Dr. med. Viktor Grünwald

ASCO 2018

Neue Guideline Geriatrisches Assessment

PD Dr. med. Peter J. Goebell

Outtakes

ASCO 2018

Outtakes

...